GlassScriptPhysician profile
Jason T Lerner
NPI 1275557191
$11,323.99
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurodevelopmental Disabilities (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,952 · 2020: $47.66 · 2021: $1,470 · 2022: $855.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $7,508.30 | 2019 | |
| Aquestive Therapeutics, INC. | $1,059.66 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $800.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $628.35 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $400.00 | 2021 | |
| Eisai INC. | $297.82 | 2019 | |
| Ucb, INC. | $245.96 | 2019-2022 | |
| Livanova USA, INC. | $161.16 | 2019 | |
| Greenwich Biosciences, INC. | $105.95 | 2019 | |
| Sunovion Pharmaceuticals INC. | $66.83 | 2019-2020 | |
| Sk Life Science, INC. | $49.96 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.